Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the cancer cell surface, limiting systemic exposure and thereby toxicity. The most commonly targeted antigens in ADCs are ERBB2, CD19, CD33, CD22, and MSLN (mesothelin).
Furthermore, over 50 distinct recognized antigens have been employed as targets in ADC. Previous research has shown that several tumor antigens are also expressed at low levels in normal cel...
